Comment from Lee Hasselbacher

Summary: The Reproductive Health Outcomes and Disparities (RHOADs) Research Lab at the University of Chicago submitted this comment in support of the petition to prevent the FDA from reducing access to mifepristone. They argue that mifepristone is a safe and effective medication and that additional regulations or restrictions would create significant barriers to care, leading to adverse health, socio-economic, and safety outcomes for patients.